NUDCD2: A Potential Drug Target and Biomarker (G134492)

Target Name: NUDCD2

NCBI ID: G134492

NUDCD2

NUDCD2: A Potential Drug Target and Biomarker

NudCD2, or NudCL2, is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. NudCD2 is a non-coding RNA molecule that has been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and survival.

One of the key features of NudCD2 is its ability to interact with a variety of different proteins, including the TGF-β1 receptor. TGF-β1 is a transcription factor that plays a role in the regulation of cellular processes such as cell growth, differentiation, and inflammation. NudCD2 has been shown to physically interact with TGF-β1 and can modulate its activity.

This interaction between NudCD2 and TGF-β1 is of particular interest in the context of cancer, as cancer is often characterized by the uncontrolled growth and proliferation of cells. NudCD2 has been shown to promote the growth and survival of various cancer cell lines, including breast, lung, and ovarian cancer. This suggests that NudCD2 may be a useful target for cancer treatment.

In addition to its role in cancer, NudCD2 has also been shown to be involved in the regulation of neurodegenerative diseases. For example, NudCD2 has been shown to be involved in the development of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. This suggests that NudCD2 may be a potential biomarker for these diseases and could be a useful target for drug development.

NudCD2 has also been shown to be involved in the regulation of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These disorders are characterized by the uncontrolled immune system, which can cause inflammation and damage to the body's tissues. NudCD2 has been shown to play a role in the regulation of immune cell function and has been implicated in the development of autoimmune disorders.

In conclusion, NudCD2 is a gene that has been identified as a potential drug target and biomarker for a variety of diseases. Its interaction with TGF-β1 and its ability to promote the growth and survival of cancer cell lines make it an attractive target for cancer treatment. In addition, its involvement in the regulation of neurodegenerative diseases and autoimmune disorders suggests that it may also be a useful biomarker for these conditions. Further research is needed to fully understand the role of NudCD2 in these diseases and to develop effective treatments.

Protein Name: NudC Domain Containing 2

Functions: May regulate the LIS1/dynein pathway by stabilizing LIS1 with Hsp90 chaperone

The "NUDCD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUDCD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets